Group 1 - The core viewpoint of the articles highlights the performance and market position of Weigao Orthopedics, noting its stock price increase and current valuation metrics [1][2] - As of July 24, Weigao Orthopedics closed at 28.42 yuan, with a 4.26% increase, and a rolling PE ratio of 47.24, marking a new low in 76 days, with a total market capitalization of 11.368 billion yuan [1] - The average PE ratio for the medical device industry is 54.56, with a median of 37.54, placing Weigao Orthopedics at the 85th position in the industry ranking [1][2] Group 2 - The company specializes in a wide range of orthopedic products, including spinal, trauma, joint, sports medicine, bone repair materials, tissue repair, and surgical instruments, making it a leading domestic enterprise in the orthopedic sector [1] - Weigao Orthopedics holds a total of 371 patents, including 86 invention patents and 266 utility model patents [1] - In the first quarter of 2025, the company reported a revenue of 290 million yuan, a year-on-year decrease of 16.59%, while net profit reached 51.789 million yuan, reflecting a year-on-year increase of 48.37%, with a gross profit margin of 63.68% [1]

7月24日，海尔生物今日收盘33.15元，上涨2.70%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到31.07倍，创76天以来新低，总市值105.40亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.56倍，行业中值37.54倍，海尔生物排 名第64位。 股东方面，截至2025年3月31日，海尔生物股东户数12793户，较上次减少453户，户均持股市值35.28万 元，户均持股数量2.76万股。 最新一期业绩显示，2025年一季报，公司实现营业收入6.89亿元，同比0.30%；净利润1.10亿元，同 比-19.88%，销售毛利率48.35%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13海尔生物31.0728.752.37105.40亿行业平均 54.5649.684.73113.96亿行业中值37.5437.872.6253.43亿1九安医疗11.1011.220.87187.29亿2英科医疗 12.5613.541.12198.43亿3新华医疗15.6514.511.28100.34亿4奥美医疗16.1315.801.6658.26亿5振德医疗 16.16 ...

7月24日，安旭生物今日收盘41.19元，上涨2.41%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到33.53倍，总市值52.35亿元。 杭州安旭生物科技股份有限公司专注于POCT试剂及仪器的研发、生产与销售。公司主要产品为POCT 试剂及仪器。公司获评"浙江省知识产权示范企业"、"国家知识产权优势企业"。2024年,新增授权专利 44项,其中发明专利13项;累计获得授权专利305项,其中发明专利43项。获得欧盟CE认证、加拿大认证、 澳大利亚认证等多项权威认证证书,新增认证606项,其中,新增国际认证592项,新增国内认证14项,累计已 取得认证1580项。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13安旭生物33.5327.221.0052.35亿行业平均 54.5649.684.73113.96亿行业中值37.5437.872.6253.43亿1九安医疗11.1011.220.87187.29亿2英科医疗 12.5613.541.12198.43亿3新华医疗15.6514.511.28100.34亿4奥美医疗16.1315.801.6658.26亿5振德医疗 16.161 ...

Group 1 - The core viewpoint of the article highlights the performance and valuation of Aibo Medical, which closed at 79.1 yuan, up 9.30%, with a rolling PE ratio of 40.47, marking a new low in 53 days, and a total market capitalization of 15.298 billion yuan [1] - Aibo Medical ranks 80th in the medical device industry based on PE ratio, with the industry average at 54.56 and the median at 37.54 [1] - As of March 31, 2025, Aibo Medical had 9,729 shareholders, a decrease of 94 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Aibo Medical focuses on the research, production, sales, and related services of ophthalmic medical devices, with main products including artificial lenses, surgical products, orthokeratology lenses, myopia control products, contact lenses, and other vision care products [1] - The latest quarterly report for Q1 2025 shows Aibo Medical achieved a revenue of 357 million yuan, a year-on-year increase of 15.07%, while net profit was 92.558 million yuan, reflecting a year-on-year decrease of 10.05%, with a gross margin of 64.60% [1]

股东方面，截至2025年3月31日，天臣医疗股东户数4443户，较上次增加68户，户均持股市值35.28万 元，户均持股数量2.76万股。 7月24日，天臣医疗今日收盘34.93元，上涨2.40%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到52.76倍，总市值28.35亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.56倍，行业中值37.54倍，天臣医疗排 名第87位。 天臣国际医疗科技股份有限公司的主营业务是专注于高端外科手术吻合器研发创新和生产销售。公司的 主要产品是腔镜吻合器类、管型吻合器类、线型切割吻合器类、荷包吻合器类、线型缝合吻合器类。公 司曾获得"苏州市级智能车间——微创外科吻合器智能制造车间"称号。 来源：金融界 最新一期业绩显示，2025年一季报，公司实现营业收入6584.61万元，同比9.34%；净利润1318.67万 元，同比16.16%，销售毛利率58.46%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13天臣医疗52.7654.634.9628.35亿行业平均 54.5649.684.73113.96亿行业中值37.5437.872 ...

Company Overview - Company name: Zhejiang Gongdong Medical Instrument Co., Ltd. specializes in the research, production, and sales of disposable medical consumables [1] - Main products include medical testing, blood collection, sampling, medical care, drug packaging, and others [1] Financial Performance - As of Q1 2025, the company reported revenue of 264 million yuan, a year-on-year decrease of 2.74% [1] - Net profit for the same period was 27.41 million yuan, down 39.23% year-on-year [1] - The sales gross margin stood at 32.40% [1] Market Position - The company's current stock price is 19.83 yuan, with a PE ratio of 28.40 times [1] - Total market capitalization is 4.372 billion yuan [1] - Compared to the industry average PE of 54.56 times and median PE of 37.54 times, the company ranks 56th in the medical device sector [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 8,909, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Core Insights - The company, Kangdelai, closed at 8.27 yuan on July 24, with a 1.10% increase, resulting in a rolling PE ratio of 16.76 times and a total market capitalization of 3.612 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 54.56 times and a median of 37.54 times, Kangdelai ranks 37th [1] - As of March 31, 2025, the number of shareholders in Kangdelai is 25,817, a decrease of 822 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Company Overview - Kangdelai specializes in the research, production, sales, and service of medical devices, including medical puncture needles and infusion devices [1] - The main product categories include puncture care, infusion catheters, indwelling infusion, puncture intervention, medical aesthetics, drug packaging materials, animal medical devices, insulin delivery, specimen collection, and active medical devices [1] - The company has established a municipal-level enterprise technology center in Shanghai and has set up a provincial-level puncture medical device research institute in Zhejiang [1] Financial Performance - In the latest quarterly report for Q1 2025, Kangdelai reported a revenue of 548 million yuan, a year-on-year decrease of 3.82%, and a net profit of 60.7042 million yuan, reflecting a year-on-year increase of 0.28% [1] - The sales gross margin for the company stands at 32.02% [1]

郑州安图生物工程股份有限公司的主营业务是体外诊断试剂及仪器的研发、制造、整合及服务。公司的 主要产品是免疫诊断试剂、免疫诊断试剂、微生物检测试剂、分子诊断检测试剂、生化试剂、仪器类。 公司入选"2023年度中国医药工业百强企业名单"，并凭借在研发成果指数与研发支持指数上的卓越表 现，在"2023年度中国医药企业研发指数百强榜单"中荣获亚军。 最新一期业绩显示，2025年一季报，公司实现营业收入9.96亿元，同比-8.56%；净利润2.70亿元，同 比-16.76%，销售毛利率65.07%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)12安图生物19.9819.072.57227.83亿行业平均 54.5649.684.73113.96亿行业中值37.5437.872.6253.43亿1九安医疗11.1011.220.87187.29亿2英科医疗 12.5613.541.12198.43亿3新华医疗15.6514.511.28100.34亿4奥美医疗16.1315.801.6658.26亿5振德医疗 16.1615.231.0358.67亿6山东药玻16.1716.211.86152.90亿7康德莱 ...

7月24日，基蛋生物今日收盘8.65元，上涨1.88%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到21.72倍，创76天以来新低，总市值43.87亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.56倍，行业中值37.54倍，基蛋生物排 名第47位。 股东方面，截至2025年3月31日，基蛋生物股东户数26747户，较上次减少451户，户均持股市值35.28万 元，户均持股数量2.76万股。 基蛋生物科技股份有限公司主要从事体外诊断试剂与仪器的研发、生产、销售及服务，是国家火炬计划 重点高新技术企业，是国内体外诊断领域（尤其是POCT领域）主要的供应商之一。公司目前主要产品 为自主研发的POCT体外诊断试剂及配套仪器。此外，发行人实现了部分生化乳胶体外诊断试剂产品试 产并开始销售。 最新一期业绩显示，2025年一季报，公司实现营业收入2.44亿元，同比-24.08%；净利润6430.74万元， 同比-25.24%，销售毛利率77.15%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13基蛋生物21.7219.621.6343.87亿行业平均 54.5649.68 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Wandong Medical, which has a current stock price of 17.8 yuan and a rolling PE ratio of 78.64 times, significantly higher than the industry average of 54.55 times [1][2] - As of March 31, 2025, Wandong Medical has 30,385 shareholders, an increase of 397 from the previous period, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, production, sales, and after-sales service of large medical imaging equipment, with its main product being medical device sales [1] Group 2 - The "Wandong WDL Wide-area Deep Learning Platform" has been implemented in several leading hospitals, including Peking University Jishuitan Hospital and Huazhong University of Science and Technology Tongji Medical College Hospital, and has received the "Craftsmanship Technology Award" for its accessibility [1] - In the first quarter of 2025, the company reported a revenue of 373 million yuan, a year-on-year increase of 21.00%, and a net profit of 35.05 million yuan, reflecting a year-on-year growth of 5.40%, with a gross profit margin of 37.75% [1] - The company ranks 99th in the medical device industry based on PE ratio, with the industry median at 37.54 times [1][2]